press center press release



Stockholm, July 31, 2014 — NASDAQ OMX (NASDAQ: NDAQ) announces that the trading in LIDDS AB (LIDDS) shares commenced today on First North at NASDAQ OMX Stockholm. LIDDS belongs to the Health Care sector and is the 27th company to be admitted to trading on First North’s Nordic markets (Stockholm, Helsinki, Copenhagen and Iceland) in 2014.

LIDDS (Local Intelligent Drug Delivery System) is a Swedish pharmaceutical company developing innovative pharmaceutical products based on medical need and its proprietary drug delivery technology. LIDDS was initially founded by researchers and entrepreneurs at Uppsala University, departments of pharmacy and material sciences and University of Gothenburg, departments of urology and oncology, and within the life-science incubator P.U.L.S. AB ( LIDDS is located in Helsingborg, Sweden, in one of Europe’s premiere biotechnology regions. For more information, visit   

Lars Åke Malmsten, CEO of LIDDS, commented: “With a successful IPO and listing on First North we can now proceed with the clinical development of our first product Liproca Depot intended for local treatment of prostate cancer and develop new applications of our proprietary drug delivery technology with a focus on localized cancer forms.

“We welcome LIDDS to NASDAQ OMX First North and to our Health Care sector,” said Adam Kostyal, Senior Vice President at NASDAQ OMX. “It is our pleasure to see that LIDDS is one of many innovative life science companies that have opted for a listing at First North. We congratulate LIDDS on their successful initial public offering, and we look forward to supporting them in their continued journey as a publicly traded company.”

LIDDS has appointed Erik Penser Bankaktiebolag as Certified Adviser.

To view an interview from today’s listing ceremony click here.

About First North

First North is regulated as a multilateral trading facility, operated by the different exchanges within NASDAQ OMX Nordic. It does not have the legal status as an EU-regulated market. Companies at First North are subject to the rules of First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market.

About NASDAQ OMX Group

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and approximately 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,400 listed companies with a market value of over $8.5 trillion and more than 10,000 corporate clients. NASDAQ OMX Nordic is not a legal entity but describes the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm and Iceland. NASDAQ OMX Nordic is not a legal entity but describes the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm and Iceland. To learn more, visit  

Cautionary Note Regarding Forward-Looking Statements

The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about futures products to be traded on NFX and NASDAQ OMX's other products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond NASDAQ OMX's control. These factors include, but are not limited to factors detailed in NASDAQ OMX's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.


Martin Hedensiö

tel. +46 (0)8 405 6254

In This Story

Nasdaq Press Center

Read the latest press releases, request a press kit, and get in touch with our press team.

learn more